ClinicalTrials.gg
CompletedNCT04750616NACAMUpdated Oct 26, 2026

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

A Phase 2 interventional study of Niacinamide and Placebo in Ischemia Reperfusion Injury, Myocardial Injury and Acute Kidney Injury, sponsored by Kaiser Permanente. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Kaiser Permanente · Phase 2, Interventional, and Prevention

How we know

Updated Oct 26, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Reperfusion Injury with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Reperfusion Injury · United States.

Enrollment
4th of 39
331 · median 30
Started
2021
the only one that year
Phase 2
11 of 44
none open now
Registered
39th of 44
by date

Among the 44 studies in Reperfusion Injury with a site in United States, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2021, is one of 11 in phase 2, and was the 39th registered.

Reperfusion Injury

260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.

Browse Reperfusion Injury studies →

Open to participants now

5 of the 44 studies in Reperfusion Injury with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Reperfusion Injury with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

Read the detailed description

This trial is a single-center, randomized, double-blind placebo-controlled Trial of Nam versus placebo in patients undergoing on-pump cardiac surgery. After screening and enrollment, patients will be stratified according to CKD status (eGFR\<45 ml/min/m2) and surgical site and randomized in a 1:1 manner to receive either Nam 3 grams or placebo on the day of surgery and post-surgical days one and two.

The overall trial duration is planned for 42 months, consisting of 39 months of active recruitment and treatment period and three months of follow-up from the last patient enrolled.

03

Conditions studied

  • Ischemia Reperfusion Injury
  • Myocardial Injury
  • Acute Kidney Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • before any study-related activities.
  • Men or women >18 years of age who are scheduled for non-emergent cardiac surgery procedures requiring CPB and are at increased risk for surgery-related adverse cardiovascular outcomes.

Procedures include:

  • CABG
  • Aortic, mitral, tricuspid, or pulmonic valve replacement or repair
  • CABG with aortic, mitral, tricuspid, and/or pulmonic valve replacement

Risk factors for surgery related to adverse cardiovascular outcomes include one or more of the following:

  • Valve surgery
  • \< 45 ml/min/1.73m2
  • Documented ≤ 35% within six months before surgery
  • Documented history of heart failure
  • Insulin-requiring diabetes
  • Non-insulin-requiring diabetes and the presence of ≥+2 proteinuria on urinalysis (or equivalent on urine protein-to-creatinine ratio or urine albumin-to-creatinine ratio)
  • Preoperative anemia ( \<11g/dl for men and women)
  • History of prior CABG
  • Age ≥65

Exclusion criteria

Exclusion Criteria

  • Preexisting AKI within seven days before surgery as defined by KDIGO stage ≥1 (serum creatinine-based)
  • Kidney transplant status
  • Off-pump cardiac surgery
  • ESRD
  • Emergent cardiac surgery
  • Pregnancy
  • Patient enrolled in competing research studies that may affect outcomes
  • Patients held in an institution by legal or official order
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Oral niacinamide

    Drug: Niacinamide

  • Placebo comparator
    Matched placebo

    Drug: Placebo

Interventions

  • Niacinamide 3 grams on the day of surgery and post-surgical days one and two

  • DrugPlacebo

    Matched placebo on the day of surgery and post-surgical days one and two

06

What researchers measure

Primary outcomes

  1. Troponin T AUC

    Troponin T AUC, composed of single daily serum measurements

    Time frame: From baseline to three days after surgery

Secondary outcomes

  1. Mean difference in uQuin/Tryp ratio AUC

    Mean difference in uQuin/Tryp ratio AUC composed of single daily serum measurements

    Time frame: From baseline to three days after surgery

  2. Mean difference in eGFR

    Mean difference in eGFR (CKD-EPI formula)

    Time frame: From baseline through day 5.

Other outcomes

  1. Number of Participants with the following Adverse Events and Serious Adverse Events

    * Postoperative dysrhythmias * Postoperative re-hospitalization. * Heart failure * Surgical wound infection * Transfusion requiring perioperative bleed * Post-surgical deep vein thrombosis and pulmonary emboli * Nosocomial infection * Nausea and vomiting * Adverse events leading to treatment discontinuation * Perioperative liver injury (x2 upper normal-limit) * Post-operative thrombosis and pulmonary emboli * Impairment of renal function (KDIGO AKI)

    Time frame: From baseline through day 90

  2. Length of index hospital stay.

    • Mean length of index hospital stay (days)

    Time frame: From baseline through day 90

  3. Length of intensive care unit stay.

    • Mean length of intensive care unit stay (days)

    Time frame: From baseline through day 90

  4. Perioperative inotropic-score and vasoactive-inotropic score.

    • Mean inotropic-score and vasoactive-inotropic score

    Time frame: At 6, 12, 24, and 48 hours post operatively

  5. Perioperative fluid volume administration.

    • Mean daily perioperative fluid volume administration

    Time frame: From baseline through day 2

  6. Perioperative brain-natriuretic peptide AUC

    BNP AUC, composed of single daily serum measurements

    Time frame: From baseline to three days after surgery

07

Study locations

1 site
  • Kaiser Permanente San Francisco Medical Center
    San Francisco, California 94115, United States
08

References and documents

Publications

  • Scurt FG, Bose K, Mertens PR, Chatzikyrkou C, Herzog C. Cardiac Surgery-Associated Acute Kidney Injury. Kidney360. 2024 Jun 1;5(6):909-926. doi: 10.34067/KID.0000000000000466. Epub 2024 May 1. PubMed 38689404 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2026, 57 months.

Of 18 phase 2 interventional studies under Reperfusion Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 57 months is above that.

Primary completion moved twice since we started tracking on Sep 25, 2026: Apr 2025 → Jun 2026, last on Oct 26, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Jun 2025 → Jun 2026, last on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 11, 2021
StartActual
Sep 13, 2021
Primary completionActual
Jun 19, 2026was Apr 2025
CompletionActual
Jun 19, 2026was Jun 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 22, 2026
Primary completion
Apr 30, 2025→Jun 19, 2026
moved 2 times, Oct 22, 2026 – Oct 26, 2026
Study completion
Jun 30, 2025→Jun 19, 2026
moved 2 times, Oct 22, 2026 – Oct 26, 2026
Enrollment
304 (estimated)→331 (actual)
Oct 22, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38689404 ↗
Oct 22, 2026
Show all 2 updates
  1. Oct 26, 2026
    Primary completion Aug 19, 2025→Jun 19, 2026
    Study completion Nov 17, 2025→Jun 19, 2026
  2. Oct 22, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38689404 ↗
    Primary completion Apr 30, 2025→Aug 19, 2025 (now actual)
    Study completion Jun 30, 2025→Nov 17, 2025 (now actual)
    Enrollment 304 (estimated)→331 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04750616
Lead sponsor
Kaiser Permanente
Responsible party
Sponsor
First posted
Feb 11, 2021
Start date
Sep 13, 2021
Primary completion
Jun 19, 2026
Completion
Jun 19, 2026
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niacinamide

Start the discussion